JF
SYRE icon

Jump Financial’s Spyre Therapeutics SYRE Stock Holding History

Jump Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,100
Closed -$454K – 2279
2025
Q3 		$454K Buy
+27,100
New +$442K 0.01% 1315
2024
Q3 		– Sell
-64,900
Closed -$1.53M – 2104
2024
Q2 		$1.53M Buy
64,900
+42,100
+185% +$1.42M 0.03% 666
2024
Q1 		$865K Buy
+22,800
New +$661K 0.02% 880

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Jump Financial's SYRE Position: Q4 2025 in Review

Jump Financial sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 27,100 shares — an estimated $454K sold.

Jump Financial first reported a position in SYRE in Q1 2024 and held it in 3 quarters. The position peaked at $1.53M in Q2 2024. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Jump Financial reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jump Financial sold 27,100 Spyre Therapeutics shares in Q4 2025, an estimated $454K.
  • Jump Financial first reported a position in Spyre Therapeutics in Q1 2024 and held it in 3 quarters.
  • Jump Financial's Spyre Therapeutics position peaked at $1.53M in Q2 2024.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Jump Financial's 13F filing for Q4 2025, filed 17 Feb 2026.